Skip to main content
. 2011 Jan 26;117(12):3294–3301. doi: 10.1182/blood-2010-08-301796

Table 4.

Results of PIA analysis and primary outcome

Phosphorylated FLT3 No. of patients No. (%) with CR/CRp
Patients with samples available for analysis 79 21 (26.6)
Inhibited at aplasia assessment 46 18 (39.1)
Not inhibited at aplasia assessment 33 3 (9.1)
Inhibited both at aplasia and outcome assessments 21 12 (57.1)

The difference in the CR/CRp rate between those who were inhibited at the aplasia assessment and those who were not was highly significant (P = .004; Fisher exact test).